Therapeutic areas in focus
Astellas plans investment of over €330m for new facility in Ireland
Astellas Pharma has announced that it is preparing to submit a planning application to build a new state-of-the-art facility at an estimated cost of €330m in Tralee, County Kerry, Ireland.
The investment is intended to expand the company’s capacity and capabilities for aseptic drug products, as well as reinforcing stable production for global supply and accelerating the development and commercialisation of new antibody drugs and other new products.
Michael Lohan, CEO at IDA, commented:
“This announcement from Astellas is excellent news for the South West region and indeed Ireland. Astellas already has a presence in both Kerry and Dublin and this significant investment of approximately €330m, adding a new state-ofthe-art aseptic drug product facility, underscores the strategic importance Ireland plays in Astellas’ global operations. The new facility in Tralee will be built with sustainability at its core and will showcase Ireland and our regional attractiveness as a location for investment.”
Hideki Shima, chief manufacturing officer at Astellas, added: “Astellas is developing innovative drugs and technologies based on our Focus Area research and development approach, placing patients at the forefront of everything we do. With the new facility, Astellas will aim to strengthen our in-house production capacity and capabilities and ensure a stable supply of high-quality Astellas medicines to patients around the world.”
The new facility will be based on the Industrial Development Authority’s (IDA) greenfield site in Kerry Technology Park, Tralee, Ireland.